Literature DB >> 20689215

Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: our experience.

Jitendra Jethani, Kenshuk Marwah, Shashank Patel, Bela Shah.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689215      PMCID: PMC2992939          DOI: 10.4103/0301-4738.67061

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Dear Editor, We read with interest the article by Taneja et al.[1] We believe that it was a great effort considering the number of studies on this particular group and no such study in our population group. There is relatively low awareness about these ophthalmic manifestations of thalassemia and this article would go a long way to create awareness about the same. We want to share our own experience (presented as a free paper in AIOC 2009, Jaipur) which is different from their findings, especially in the untreated and treated group with desferioxamine. A total of 112 children (224 eyes) with beta thalassemia were taken for the study. Ninety-five children (190 eyes, 84.8%) not on desferioxamine therapy were termed as case group and 17 children (34 eyes, 15.2%) were on desferioxamine and called control group. Out of 95 children, 62 (65.2%) were male. All children were under the age of 15 years (4-15 years) who had received multiple blood transfusions. Conjunctival blanching and isolated cataractous changes in the lens were the most common anterior segment findings in the untreated group. Both were found in 12 (6.3%) eyes. The rest of the findings are listed in Table 1. In the group on desferioxamine, none of these children had any opacity in the lens. Four (11.8%) had tessellated fundus in the control group.
Table 1

Various ocular manifestations in the untreated group

Anterior segment findingsNo. of eyes (%)Posterior segment findingsNo. of eyes (%)
Conjunctival Blanching12 (6.3)Tessellated fundus55 (28.9)
Lens opacities12 (6.3)Temporal pallor8 (4.2)
Xerosis/ Bitot’s spot8 (4.2)Area of pigmentation6 (3.1)
Heterochromia4 (2.1)Albinotic fundus4 (2.1)
Pseduophakia2 (1)Nevus2 (1)
Abduction deficit (lateral rectus underaction)2 (1)Venous dilatation2 (1)
Telecanthus2 (1)Nasal tilting1 (0.5)
Persistent1 (0.5)Snow flake degeneration1 (0.5)
Pupillary membraneArea of depigmentation1 (0.5)
Sheathing1 (0.5)
Various ocular manifestations in the untreated group The ocular manifestations were compared in the untreated group with respect to serum ferritin [Table 2]. We compared our data with other studies and found lens opacities were commoner in our study (14 eyes 7.3%).
Table 2

The distribution of various ocular manifestation visa-vis ferritin levels

Serum ferritinLess than 500501-9991000-49995000 and above
Anterior segment findings No. of affected eyes (%)Conjunctival Blanching12 (6.3)
Lens opacities2 (1)10 (5)
Conjunctival Blanching12 (6.3)
Xerosis/ Bitot’s spot8 (4.2)
Heterochromia Telecanthus4 (2.1)
Posterior segment findings No. of affected eyes (%)Tessellated fundus3 (1.6)
Temporal pallor2 (1)
Area of pigmentation
Albinotic fundus1 (0.5)1 (0.5)3 (1.6)2 (1)
Nevus1 (0.5)1 (0.5)
Venous dilatation1 (0.5)
The distribution of various ocular manifestation visa-vis ferritin levels Goldberg et al.[2] did not find a single case with lens opacity. However, his patients were mainly with sickle cell hemoglobinopathy and not beta thalassemia patients. Degeneration of retinal pigment epithelium (RPE) and tessellated fundus were common in our study as has been noted in a previous study by Gartaganis et al.[3] We could not find a single case with angioid streaks even when our case series was larger. We saw untreated cases and therefore, could see that the effects on the eye were mainly because of the iron overload and not secondary to chelating therapy as has been thought. We could not find a single case of lens opacities in children (small sample size) with reduced serum ferritin levels. All these children were on chelating therapy. Ocular manifestation in control group was significantly lower and it was comparable to other studies. This suggests that serum ferritin levels and iron load may not be actually responsible for the ocular manifestations of beta thatlessemia. Our study absolves desferioxamine of any role in causing ocular surface disorders. Rather, it is the disease itself which may be responsible for any such disorder. Desferioxamine may be considered safe so far as the eye is concerned. However, since our sample size was small, such results should be interpreted with caution.
  3 in total

1.  Ophthalmologic manifestations of sickle cell thalassemia.

Authors:  M F Goldberg; S Charache; I Acacio
Journal:  Arch Intern Med       Date:  1971-07

2.  Ocular abnormalities in patients with beta thalassemia.

Authors:  S Gartaganis; K Ismiridis; O Papageorgiou; N G Beratis; D Papanastasiou
Journal:  Am J Ophthalmol       Date:  1989-12-15       Impact factor: 5.258

3.  Multiple transfused thalassemia major: ocular manifestations in a hospital-based population.

Authors:  Rashi Taneja; Pankaj Malik; Mamta Sharma; Mahesh C Agarwal
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

  3 in total
  9 in total

1.  Ocular findings in children with thalassemia major in Eastern Mediterranean.

Authors:  Adnan Aksoy; Murat Aslankurt; Lokman Aslan; Ozlem Gül; Mesut Garipardıç; Oğuz Celik; Seydi Okumuş; Murat Ozdemir; Gökhan Ozdemir
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

2.  Ocular manifestations in patients with transfusion-dependent β-thalassemia.

Authors:  F Akritidou; A Praidou; T Papamitsou; V Kozobolis; G Labiris
Journal:  Hippokratia       Date:  2021 Apr-Jun       Impact factor: 0.522

3.  Refractive errors and ocular biometry components in thalassemia major patients.

Authors:  Samira Heydarian; Reza Jafari; Hosein Karami
Journal:  Int Ophthalmol       Date:  2015-12-08       Impact factor: 2.031

Review 4.  β-Thalassemia and ocular implications: a systematic review.

Authors:  Aliki Liaska; Petros Petrou; Constantinos D Georgakopoulos; Ramza Diamanti; Dimitris Papaconstantinou; Menelaos G Kanakis; Ilias Georgalas
Journal:  BMC Ophthalmol       Date:  2016-07-08       Impact factor: 2.209

5.  Anterior Chamber Angle, Intraocular Pressure, and Globe Biometric Parameters in the Children with β-Thalassemia Major.

Authors:  Nermien Sm El-Haddad
Journal:  J Curr Glaucoma Pract       Date:  2020 Jan-Apr

6.  Evaluation of Corneal Epithelial Thickness and Dry Eye Disease Tests in Thalassemic Adolescents.

Authors:  Weam Mohamed Ebeid; Mahmoud Adel Kenny; Tamer AbdelFattah Badran
Journal:  Clin Ophthalmol       Date:  2021-04-06

7.  Ocular abnormalities in multi-transfused beta-thalassemia patients.

Authors:  Reza Jafari; Samira Heydarian; Hosein Karami; Mohammad Momeni Shektaei; Kiumars Noruzpour Dailami; Ahmad Ahmadzadeh Amiri; Majid Reza Sheikh Rezaee; Asad Allah Farrokh Far
Journal:  Indian J Ophthalmol       Date:  2015-09       Impact factor: 1.848

8.  Ocular findings in patients with transfusion-dependent β-thalassemia in southern Iran.

Authors:  Sezaneh Haghpanah; Omid Reza Zekavat; Mohammadreza Bordbar; Mehran Karimi; Soheila Zareifar; Sanaz Safaei; Mani Ramzi; Hossein Ashraf
Journal:  BMC Ophthalmol       Date:  2020-09-22       Impact factor: 2.209

9.  Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major.

Authors:  Raffaele Nuzzi; Giada Geronazzo; Federico Tridico; Alessia Nuzzi; Paolo Caselgrandi; Antonio Giulio Piga
Journal:  Clin Ophthalmol       Date:  2021-05-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.